-transparent.png){kind=logo}
The benefits of using antiarrhythmic response to optimize dosage regimens of antiarrhythmic drugs in individual patients have been examined. Graded antiarrhythmic response and simultaneously measured plasma drug concentrations have been obtained in 15 patients receiving multiple oral doses of a new antiarrhythmic, tocainide. Plasma drug concentration-antiarrhythmic response data from each of 11 subjects responding to the drug have been fitted by a generalized concentration effect function which is valid over the entire range of response. With the use of experimentally determined pharmacokinetic parameters to define the dose-plasma concentration relationship and plasma drug concentration-response parameters estimated for individual patients, simulations were carried out to show the effect of various dosage regimens on antiarrhythmic response in individual patients. Such simulations provide a means of assessing antiarrhythmic effect in the range of clinical interest (80% to 100% of maximum effect), where the antiarrhythmic effect is a nonlinear function of dose, plasma drug concentration, or their logarithms. The simulations also demonstrate that for identical daily doses and dosing intervals patients show marked variability in antiarrhythmic response.
P J Meffin, and
R A Winkle, and
T F Blaschke, and
J Fitzgerald, and
D C Harrison, and
S R Harapat, and
P A Bell
April 1978,
The American journal of cardiology,
P J Meffin, and
R A Winkle, and
T F Blaschke, and
J Fitzgerald, and
D C Harrison, and
S R Harapat, and
P A Bell
January 1985,
Drug intelligence & clinical pharmacy,
P J Meffin, and
R A Winkle, and
T F Blaschke, and
J Fitzgerald, and
D C Harrison, and
S R Harapat, and
P A Bell
April 1987,
Canadian journal of psychiatry. Revue canadienne de psychiatrie,
P J Meffin, and
R A Winkle, and
T F Blaschke, and
J Fitzgerald, and
D C Harrison, and
S R Harapat, and
P A Bell
September 1985,
Annals of internal medicine,
P J Meffin, and
R A Winkle, and
T F Blaschke, and
J Fitzgerald, and
D C Harrison, and
S R Harapat, and
P A Bell
June 1976,
Clinical pharmacology and therapeutics,
P J Meffin, and
R A Winkle, and
T F Blaschke, and
J Fitzgerald, and
D C Harrison, and
S R Harapat, and
P A Bell
August 1983,
Acta pharmacologica et toxicologica,
P J Meffin, and
R A Winkle, and
T F Blaschke, and
J Fitzgerald, and
D C Harrison, and
S R Harapat, and
P A Bell
May 1989,
The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society,
P J Meffin, and
R A Winkle, and
T F Blaschke, and
J Fitzgerald, and
D C Harrison, and
S R Harapat, and
P A Bell
July 1985,
The Western journal of medicine,
P J Meffin, and
R A Winkle, and
T F Blaschke, and
J Fitzgerald, and
D C Harrison, and
S R Harapat, and
P A Bell
July 1986,
The New England journal of medicine,
P J Meffin, and
R A Winkle, and
T F Blaschke, and
J Fitzgerald, and
D C Harrison, and
S R Harapat, and
P A Bell
December 1980,
American heart journal,
